Introduction Drug-induced liver injury due to chemotherapy is an important cause of
morbidity in cancer patients, although its clinical manifestations are poorly understood …

Background Data on drug‐induced liver injury (DILI) and acute liver failure (ALF) in modern
phase 1 oncology trials are limited, specifically with respect to the incidence and resolution …

Aims Mirvetuximab soravtansine is a first‐in‐class antibody–drug conjugate recently
approved for the treatment of folate receptor‐α positive ovarian cancer. The aim of this study …

Tralokinumab is the first biologic therapy for moderate‐to‐severe atopic dermatitis (AD) that
specifically neutralizes interleukin‐13 activity, a key driver of AD signs and symptoms …

The liver is a vital organ that plays a central role in the metabolism and elimination of drug
molecules. Impairment of this vital organ can lead to increased accumulation of parent drug …

Multiple myeloma is an incurable progressive neoplastic disease that accounts for 10% of all
hematologic malignancies. Even though significant progress has been made in the …

Introduction: Fibrolamellar carcinoma (FLC) displays upregulation of several oncogenes,
including HER2, and multiple immune-suppressive mechanisms. We investigated the …

This clinical trial was designed to evaluate the effect of moderate or severe hepatic
impairment on the single‐dose pharmacokinetics (PK) of the investigational anticancer …

Introduction The goal of organ dysfunction Phase I trials is to characterize the safety and
pharmacokinetics of novel agents in cancer patients with liver or kidney dysfunction, but the …

Pharmacokinetics (PK) studies enable drug developers to elucidate the relationship of dose
to blood concentrations of drugs in various patient populations and determine the need for …